BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34933652)

  • 21. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
    Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
    Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.
    Yu Y; Zhang T; Bao X; Wang Q; Zhang L; Hong Y; Zeng Z; Shen H; Wu D; Pan J; Liu H; Chen S; Sun A
    Leuk Lymphoma; 2020 Apr; 61(4):919-926. PubMed ID: 31842651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic models in myelodysplastic syndromes.
    Bejar R
    Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
    Nazha A; Bejar R
    Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
    DeZern AE; Greenberg PL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
    Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.
    Bektaş Ö; Üner A; Eliaçık E; Uz B; Işık A; Etgül S; Bozkurt S; Haznedaroğlu İC; Göker H; Sayınalp N; Aksu S; Demiroğlu H; Özcebe Oİ; Büyükaşık Y
    Turk J Haematol; 2016 Jun; 33(2):119-26. PubMed ID: 26376664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
    Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
    Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
    Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors and their relationship to prognosis in myelodysplastic syndromes.
    Greenberg PL
    Leuk Res; 1998 May; 22 Suppl 1():S3-6. PubMed ID: 9734692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
    Hoff FW; Madanat YF
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
    Zeidan AM; Al Ali N; Barnard J; Padron E; Lancet JE; Sekeres MA; Steensma DP; DeZern A; Roboz G; Jabbour E; Garcia-Manero G; List A; Komrokji R
    Leukemia; 2017 Jun; 31(6):1391-1397. PubMed ID: 28111463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
    Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
    Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.